Spero Therapeutics Inc
NASDAQ:SPRO

Watchlist Manager
Spero Therapeutics Inc Logo
Spero Therapeutics Inc
NASDAQ:SPRO
Watchlist
Price: 2.45 USD -2.39% Market Closed
Market Cap: 138m USD

Operating Margin
Spero Therapeutics Inc

-111.2%
Current
-121%
Average
-4.7%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-111.2%
=
Operating Profit
-45.1m
/
Revenue
40.5m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Spero Therapeutics Inc
NASDAQ:SPRO
138m USD
-111%
IL
Can Fite Biopharma Ltd
TASE:CANF
154.5T ILS
-1 487%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
391.8B USD
33%
US
Amgen Inc
NASDAQ:AMGN
174.5B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
151.2B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.5B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.9B USD
28%
AU
CSL Ltd
ASX:CSL
84B AUD
26%
NL
argenx SE
XBRU:ARGX
42.7B EUR
22%
No Stocks Found

Spero Therapeutics Inc
Glance View

Market Cap
138m USD
Industry
Biotechnology

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. The company is headquartered in Cambridge, Massachusetts and currently employs 146 full-time employees. The company went IPO on 2017-11-02. The firm is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. Its lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide), is developed as the oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). The company is also developing SPR720 as a novel oral therapy product candidate for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. The firm also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting.

SPRO Intrinsic Value
0.14 USD
Overvaluation 94%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-111.2%
=
Operating Profit
-45.1m
/
Revenue
40.5m
What is the Operating Margin of Spero Therapeutics Inc?

Based on Spero Therapeutics Inc's most recent financial statements, the company has Operating Margin of -111.2%.

Back to Top